Collaboration in Healthcare
Healthcare Innovation Starts with Collaboration
If you're searching for a strong partner for your next project, look no further than Merck KGaA, Darmstadt, Germany. Whether it’s an early-stage licensing opportunity, new technology or strategic research alliance, we’re actively seeking partnerships with like-minded organizations – those that value trust, transparency and mutually rewarding relationships, with the ambition to increase the value of each partnership.We are focused on broadening our access to the world of scientific and product innovation beyond our own laboratories, and are interested in extending our global and regional commercial portfolio. If you are looking for a partner either to bring your competitive portfolio of investigational products to the market, or to fully exploit the potential of your commercial products, we’d love to hear from you.
Strategy in Action
In order to achieve our strategic business objectives, we are aiming to invest energy and resources in the following partnerships, key franchises and markets.
Building our Bench Strength
We are committed to a collaborative R&D model, forging partnerships with academic, research institutions, and biotech and pharma companies to bring new therapies to patients. With roughly 50% of our pipeline developed through collaborations, we value the innovative spirit that exists both inside our walls and around the ecosystem of healthcare.
Related NewsView All News
Merck KGaA, Darmstadt, Germany has entered into an out-licensing agreement with MoonLake Immunotherapeutics AG for sonelokimab (M1095).
Merck KGaA, Darmstadt, Germany today announced a new analysis from the MAGNIFY-MS sub-study showing a specific immune repopulation pattern in patients with relapsing multiple sclerosis treated with MAVENCLAD®
Merck KGaA, Darmstadt, Germany will present data from a Phase II placebo-controlled randomized trial at the 2021 American Academy of Neurology (AAN) Annual Meeting.